keyword
MENU ▼
Read by QxMD icon Read
search

Cancer and immune

keyword
https://www.readbyqxmd.com/read/28654899/tumor-reductive-therapies-and-antitumor-immunity
#1
REVIEW
Huiqin Guo, Kangla Tsung
Tumor reductive therapy is to reduce tumor burden through direct killing of tumor cells. So far, there is no report on the connection between antitumor immunity and tumor reductive therapies. In the last few years, a new category of cancer treatment, immunotherapy, emerged and they are categorized separately from classic cytotoxic treatments (chemo and radiation therapy). The most prominent examples include cellular therapies (LAK and CAR-T) and immune checkpoint inhibitors (anti-PD-1 and CTLA-4). Recent advances in clinical immunotherapy and our understanding of the mechanism behind them revealed that these therapies have a closer relationship with classic cancer treatments than we thought...
June 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28653974/hla-g-3-utr-polymorphisms-predict-drug-induced-g3-4-toxicity-related-to-folinic-acid-5-fluorouracil-oxaliplatin-folfox4-chemotherapy-in-non-metastatic-colorectal-cancer
#2
Marica Garziera, Saverio Virdone, Elena De Mattia, Lucia Scarabel, Erika Cecchin, Jerry Polesel, Mario D'Andrea, Nicoletta Pella, Angela Buonadonna, Adolfo Favaretto, Giuseppe Toffoli
Polymorphisms in drug-metabolizing enzymes might not completely explain inter-individual differences in toxicity profiles of patients with colorectal cancer (CRC) that receive folinic acid/5-fluorouracil/oxaliplatin (FOLFOX4). Recent data indicate that the immune system could contribute to FOLFOX4 outcomes. In light of the immune inhibitory nature of human leukocyte antigen-G (HLA-G), a non-classical major histocompatibility complex (MHC) class I molecule, we aimed to identify novel genomic markers of grades 3 and 4 (G3-4) toxicity related to FOLFOX4 therapy in patients with CRC...
June 27, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28653896/ganoderma-lucidum-targeting-lung-cancer-signaling-a-review
#3
Balraj Singh Gill, Navgeet, Sanjeev Kumar
Lung cancer causes huge mortality to population, and pharmaceutical companies require new drugs as an alternative either synthetic or natural targeting lung cancer. The conventional therapies cause side effects, and therefore, natural products are used as a therapeutic candidate in lung cancer. Chemical diversity among natural products highlights the impact of evolution and survival of fittest. One such neglected natural product is Ganoderma lucidum used for promoting health and longevity for a longer time...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28653677/monitoring-immune-checkpoint-blockade-response-evaluation-and-biomarker-development
#4
REVIEW
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. The promising antitumour activity of monoclonal antibodies targeting the immune-checkpoint proteins CTLA-4, PD-1, and PD-L1 led to regulatory approvals of these agents for the treatment of a variety of malignancies. Patients might experience clinical benefits from treatment with these agents, despite unconventional patterns of tumour response that can be misinterpreted as disease progression, warranting a new, specific approach to evaluate responses to immunotherapy...
June 27, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28653574/combination-of-sorafenib-and-cytokine-induced-killer-cells-in-metastatic-renal-cell-carcinoma-a-potential-regimen
#5
Yonghao Yang, Hongwei Lin, Lingdi Zhao, Yongping Song, Quanli Gao
Metastatic renal cell carcinoma (MRCC) exhibits primary resistance to both chemotherapy and radiotherapy. As an immunogenic cancer, MRCC is relatively sensitive to immunotherapy such as that with cytokines, immune checkpoint inhibitors and adoptive T-cell therapy. In addition, many targeted agents developed over the past decade exhibit greater efficacy than cytokines and have become the standard first-line therapy for MRCC. Several preclinical studies have shown that the targeted agent sorafenib possesses an immunomodulation function and may be suitable for combination with immunotherapy...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653573/the-future-of-immune-checkpoint-cancer-therapy-after-pd-1-and-ctla-4
#6
Andrew W Hahn, David M Gill, Sumanta K Pal, Neeraj Agarwal
The adaptive immune system plays an important role in eradicating malignant cells. Co-stimulatory and co-inhibitory signals to T cells though immune checkpoint receptors are involved in tumorigenesis and metastasis. Exploitation of immune checkpoint inhibitors, PD-1 and CTLA-4, with monoclonal antibodies has created impressive clinical responses. Many other immune checkpoint co-inhibitors and co-stimulators exist, including the B7 superfamily and tumor necrosis factor receptors superfamily. Here, we will examine co-inhibitors and co-stimulators beyond PD-1 and CTLA-4 that are being investigated in active clinical trials...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653570/the-second-wave-of-immune-checkpoint-inhibitor-tsunami-advance-challenges-and-perspectives
#7
Hampig Raphael Kourie, Gil Awada, Ahmad Awada
After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death protein 1 and anti-PDL1 approved by the FDA, the positive clinical trials published and the abstracts reported at important scientific meetings during 2016. Then, we highlighted the updates on debatable issues related to checkpoint inhibitors, since the first wave published in a previous issue...
June 2017: Immunotherapy
https://www.readbyqxmd.com/read/28653522/-immunotherapy-and-non-small-cell-lung-cancer-a-r-evolution
#8
T Berghmans, A P Meert
Immunotherapy renews in non-small cell lung cancer. Antibodies directed against PD1 and PD-L1, blocking the relationship between the cancer cells and the immune system, allowed in randomised trials to significantly improve cancer control with an interesting survival impact of treated patients. However, it remains to determine the most benefiting populations from this expensive and potentially toxic therapy.
2017: Revue Médicale de Bruxelles
https://www.readbyqxmd.com/read/28653032/paraneoplastic-antigens-as-biomarkers-for-early-diagnosis-of-ovarian-cancer
#9
REVIEW
Madhumita Chatterjee, Laura C Hurley, Michael A Tainsky
Paraneoplastic syndromes are a group of rare disorders that can be triggered by an abnormal immune response to proteins from tumors of the lung, ovary, lymphatics, or breast. Paraneoplastic clinical syndromes affect < 1% of patients with cancer; however, the frequency of subclinical levels of paraneoplastic autoantibodies in asymptomatic patients with cancer is unknown. Numerous studies have reported that ovarian cancer patients show signs of paraneoplastic neurological syndromes (PNSs) before or after their cancers are diagnosed...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28652651/molecular-mimicry-in-helicobacter-pylori-infections
#10
REVIEW
Magdalena Chmiela, Weronika Gonciarz
Gram-negative bacteria Helicobacter pylori (H. pylori) colonize gastric mucosa in humans and increase the risk of serious diseases such as gastric and duodenal ulcers, stomach cancers and mucosa associated lymphoid tissue lymphoma. The role of H. pylori infection in the pathogenesis of several extragastric diseases has been suggested including immune thrombocytopenic purpura, iron deficiency anemia, vitamin D deficiency, cardiovascular diseases, diabetes mellitus and dermatological disorders. Also neurological diseases and even lung cancer have attracted researchers concern...
June 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28652455/rapid-progressive-disease-after-nivolumab-therapy-in-three-patients-with-metastatic-renal-cell-carcinoma
#11
Yuki Kobari, Tsunenori Kondo, Toshio Takagi, Kenji Omae, Hayakazu Nakazawa, Kazunari Tanabe
BACKGROUND/AIM: Rapid progressive disease (RPD), accelerated tumour growth immediate after the initiation of immune checkpoint inhibitor therapy, has been reported in melanoma and lung cancer. Herein, we describe 3 cases of RPD during the initial phase of nivolumab treatment for metastatic renal cell carcinoma. PATIENTS AND METHODS: The first and second patients received nivolumab in the fourth-line setting. The third patient received nivolumab therapy as third-line treatment...
July 2017: In Vivo
https://www.readbyqxmd.com/read/28652399/c-rel-and-i%C3%AE%C2%BAbns-govern-common-and-independent-steps-of-regulatory-t-cell-development-from-novel-cd122-expressing-pre-precursors
#12
Marc Schuster, Carlos Plaza-Sirvent, Anne-Marie Matthies, Ulrike Heise, Andreas Jeron, Dunja Bruder, Alexander Visekruna, Jochen Huehn, Ingo Schmitz
Foxp3-expressing regulatory T cells (Tregs) are essential regulators of immune homeostasis and, thus, are prime targets for therapeutic interventions of diseases such as cancer and autoimmunity. c-REL and IκBNS are important regulators of Foxp3 induction in Treg precursors upon γ-chain cytokine stimulation. In c-REL/IκBNS double-deficient mice, Treg numbers were dramatically reduced, indicating that together, c-REL and IκBNS are pivotal for Treg development. However, despite the highly reduced Treg compartment, double-deficient mice did not develop autoimmunity even when aged to more than 1 y, suggesting that c-REL and IκBNS are required for T cell effector function as well...
June 26, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28652380/immune-escape-in-breast-cancer-during-in-situ-to-invasive-carcinoma-transition
#13
Carlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, Anne Trinh, Lin L Liu, Francisco Beca, Xiaoyuan Zi, Minsuk Kwak, Helga Bergholtz, Ying Su, Lina Ding, Hege G Russnes, Andrea L Richardson, Kirsten Babski, Elizabeth Min Hui Kim, Charles McDonnell, Jon Wagner, Ron Rowberry, Gordon J Freeman, Deborah Dillon, Therese Sorlie, Lisa M Coussens, Judy E Garber, Rong Fan, Kristie Bobolis, D Craig Allred, Joon Jeong, So Yeon Park, Franziska Michor, Kornelia Polyak
To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils. Gene expression profiling of CD45+CD3+ T cells demonstrated a decrease in CD8+ signatures in IDCs. Immunofluorescence analysis showed fewer activated GZMB+CD8+ T cells in IDC than in DCIS, including in matched DCIS recurrent IDC...
June 26, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28652280/immune-related-adverse-events-as-a-biomarker-in-non-melanoma-patients-treated-with-programmed-cell-death-1-inhibitors
#14
Julia Judd, Matthew Zibelman, Elizabeth Handorf, John O'Neill, Chethan Ramamurthy, Sasini Bentota, Jamie Doyle, Robert G Uzzo, Jessica Bauman, Hossein Borghaei, Elizabeth R Plimack, Ranee Mehra, Daniel M Geynisman
BACKGROUND: The programmed death 1 (PD-1) checkpoint inhibitors (CKIs) can lead to immune-related adverse events (irAEs). We sought to evaluate whether the development of irAEs correlates with treatment response in non-melanoma malignancies. MATERIALS AND METHODS: We conducted a retrospective study of patients who received anti-PD-1 CKI monotherapy at Fox Chase Cancer Center. Endpoints included overall response rate (ORR), time to next therapy or death (TTNTD), and overall survival (OS)...
June 26, 2017: Oncologist
https://www.readbyqxmd.com/read/28652244/targeting-adenosine-in-braf-mutant-melanoma-reduces-tumor-growth-and-metastasis
#15
Arabella Young, Shin Foong Ngiow, Jason Madore, Julia Reinhardt, Jennifer Landsberg, Arash Chitsazan, Jai Rautela, Tobias Bald, Deborah Barkauskas, Elizabeth Ahern, Nicholas Huntington, Dirk Schadendorf, Georgina V Long, Glen M Boyle, Michael Hölzel, Richard A Scolyer, Mark J Smyth
Increasing evidence exists for the role of immunosuppressive adenosine in promoting tumor growth and spread in a number of cancer types, resulting in poor clinical outcomes. In this study, we assessed whether the CD73-adenosinergic pathway is active in melanoma patients and whether adenosine restricts the efficacy of clinically approved targeted therapies for commonly mutated BRAF(V600E) melanoma. In AJCC Stage III melanoma patients, CD73 expression (the enzyme that generates adenosine) correlated significantly with patients presenting nodal metastatic melanoma, suggesting that targeting this pathway may be effective in advanced stage disease...
June 26, 2017: Cancer Research
https://www.readbyqxmd.com/read/28651910/taming-the-immune-system-through-transfusion-in-oncology-patients
#16
REVIEW
Seyed Mohammad Amin Kormi, Jerard Seghatchian
Blood transfusion is a clinical replacement therapy with many successes with some benefit and, also, some harm. Cancer is a multifaceted disease potentially associated with the immune system's weakness where the cancerous tumor cells escape from the immune system. Allogeneic blood transfusion, through five major mechanisms including the lymphocyte-T set, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), natural killer cells (NKCs), and dendritic cells (DCs) can help the recipient's defense mechanisms...
May 26, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28651499/necroptosis-in-cancer-an-angel-or-a-demon
#17
Tianzhen Wang, Yinji Jin, Weiwei Yang, Lei Zhang, Xiaoming Jin, Xi Liu, Yan He, Xiaobo Li
In the past few decades, apoptosis has been regarded as the only form of programmed cell death. However, the traditional view has been challenged by the identification of several forms of regulated necrosis, including necroptosis. Necroptosis is typified by a necrotic cell death morphology and is controlled by RIP1, RIP3, and mixed lineage kinase domain-like protein. The physiological role of necroptosis is to serve as a "fail-safe" form of cell death for cells that fail to undergo apoptosis during embryonic development and disease defense...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28651328/acute-coronary-syndrome-as-a-possible-immune-related-adverse-event-in-a-lung-cancer-patient-achieving-a-complete-response-to-anti-pd-1-immune-checkpoint-antibody
#18
Y Tomita, D Sueta, Y Kakiuchi, S Saeki, K Saruwatari, S Sakata, T Jodai, Y Migiyama, K Akaike, S Hirosako, K Fujisue, S Yamamura, S Miyazaki, S Takashio, Y Izumiya, K Nakamura, K Tsujita, H Ichiyasu, K Fujii
No abstract text is available yet for this article.
June 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28651116/pd-1-pd-l1-and-ctla-4-in-pregnancy-related-and-in-early-onset-breast-cancer-a-comparative-study
#19
Balázs Ács, Lilla Madaras, Anna-Mária Tőkés, Attila Kristóf Kovács, Erzsébet Kovács, Magdolna Ozsvári-Vidákovich, Ádám Karászi, Ede Birtalan, Magdolna Dank, Attila Marcell Szász, Janina Kulka
PURPOSE: We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. METHODS: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were evaluated with immunohistochemistry (IHC) on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8)...
June 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28651074/chimeric-antigen-receptor-engineered-natural-killer-and-natural-killer-t-cells-for-cancer-immunotherapy
#20
REVIEW
Dominique Bollino, Tonya J Webb
Natural killer (NK) cells of the innate immune system and NK T (NKT) cells, which have roles in both the innate and adaptive responses, are unique lymphocyte subsets that have similarities in their functions and phenotypes. Both cell types can rapidly respond to the presence of tumor cells and participate in immune surveillance and antitumor immune responses. This has incited interest in the development of novel cancer therapeutics based on NK and NKT cell manipulation. Chimeric antigen receptors (CARs), generated through the fusion of an antigen-binding region of a monoclonal antibody or other ligand to intracellular signaling domains, can enhance lymphocyte targeting and activation toward diverse malignancies...
June 9, 2017: Translational Research: the Journal of Laboratory and Clinical Medicine
keyword
keyword
94986
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"